$SRRK News

Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026

JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $63

Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target

Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date

HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $60

Scholar Rock Removes Catalent Indiana From Apitegromab BLA After FDA OAI Classification; FDA Review Remains On Track for Sept. 30 PDUFA Using Second Fill-Finish Site

Scholar Rock Q2 Earnings Call Highlights

Scholar Rock Holding Corp (SRRK) (Q2 2026) Earnings Call Highlights: Dual Paths to FDA Approval ...

Scholar Rock (NASDAQ:SRRK) Rallies 17% as Regulatory Catalysts Outweigh In-Line Q2 Results

Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock Holding Q2 EPS $(0.84) Beats $(0.85) Estimate; Cash Balance Of $492M

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Scholar Rock Holding (SRRK) Pulls Back Following A Strong Run, Is It Trading At A Discount?

Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

Scholar Rock Announces European Medicines Agency Reviewing Apitegromab Marketing Authorisation Application To Treat Spinal Muscular Atrophy; Committee For Medicinal Products For Human Use Anticipated Later This Year If FDA Reclassifies Catalent Indiana

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)